Canada has approved Amylyx Pharmaceuticals' treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, the drugmaker said on Monday, the first such approval for the oral drug.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,